开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09939 开拓药业-B

已收盘 08-13 16:08:12

1.850

-0.050

-2.63%

最高1.985	最低1.850	成交量55.75万
今开1.900	昨收1.900	日振幅7.11%
总市值9.23亿	流通市值9.23亿	总股本4.99亿
成交额106.89万	换手率0.11%	流通股本4.99亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09939","market":"HK","secType":"STK","nameCN":"开拓药业-B","latestPrice":1.85,"timestamp":1786608492801,"preClose":1.9,"halted":0,"volume":557500,"delay":0,"changeRate":-0.02631578947368412,"floatShares":499000000,"shares":499000000,"eps":-0.5176494489425982,"marketStatus":"已收盘","change":-0.05,"latestTime":"08-13 16:08:12","open":1.9,"high":1.985,"low":1.85,"amount":1068852,"amplitude":0.071053,"askPrice":1.9,"askSize":10000,"bidPrice":1.85,"bidSize":22500,"shortable":0,"etf":0,"ttmEps":-0.5165953152587593,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786671000000},"marketStatusCode":5,"adr":0,"listingDate":1590076800000,"exchange":"SEHK","adjPreClose":1.9,"openAndCloseTimeList":[[1786584600000,1786593600000],[1786597200000,1786608000000]],"volumeRatio":0.529792,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09939","defaultTab":"news","newsList":[{"id":"2659155541","title":"亚虹医药：APL-2501临床试验申请获FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2659155541","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659155541?lang=zh_cn&edition=full","pubTime":"2026-08-13 18:40","pubTimestamp":1786617611,"startTime":"0","endTime":"0","summary":"亚虹医药(688176.SH)公告称，公司控股子公司Baylink Biosciences Inc收到美国FDA关于同意开展公司自主研发的APL-2501(化合物名称BLB101)用于治疗晚期实体瘤临床试验的函告。APL-2501是公司自主研发的搭载专有亲水性连接子、基于拓扑异构酶抑制剂的抗CLDN6/9抗体药物偶联物(ADC)，可用于治疗包括卵巢癌、非小细胞肺癌、子宫内膜癌、胃癌等多种晚期实体瘤。本次获批对公司近期业绩不会产生重大影响。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081300032598.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1574","159938","09939","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659153539","title":"市场冲高回落，医药板块逆势活跃，关注沪深300ETF易方达（510310）后续走势","url":"https://stock-news.laohu8.com/highlight/detail?id=2659153539","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659153539?lang=zh_cn&edition=full","pubTime":"2026-08-13 18:11","pubTimestamp":1786615907,"startTime":"0","endTime":"0","summary":"8月13日，市场冲高回落，A股三大指数尾盘翻绿，全市场成交额约2.6万亿元。板块题材上，医疗服务、创新药、生物制品等板块表现活跃，贵金属、教育、工业金属、房地产等板块纷纷下挫。港股方面，主要指数涨跌不一，计算机设备、IT服务等板块涨幅居前。截至收盘，中证A500指数下跌0.8%，沪深300指数下跌0.6%，创业板指数下跌0.5%，上证科创板50成分指数下跌1.1%，恒生中国企业指数下跌0.2%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/SS2026081300032056.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","510310","09939","BK1574","BK1161","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659305131","title":"新股前瞻|核心产品已获吉利德订单，勤浩医药能否拿到港股入场券？","url":"https://stock-news.laohu8.com/highlight/detail?id=2659305131","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659305131?lang=zh_cn&edition=full","pubTime":"2026-08-13 17:11","pubTimestamp":1786612261,"startTime":"0","endTime":"0","summary":"授权收入驱动短期扭亏，研发投入持续加码从财务数据来看，勤浩医药目前尚无商业化产品收入，营收主要来源于对外授权合作。毛利变动与收入趋势一致。勤浩医药的RAS信号通路管线以GH21、GH55及临床前候选药物GH58为代表。安全性方面，不良事件及各项检查数据表明GH21耐受性良好。即使获得附注条件批准，公司仍需完成确证性临床试验，若后续未能证明临床获益，可能面临撤回上市许可的风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479524.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK1161","159938","BK1515","VXUS","09939","BK1574","KCAI","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659375901","title":"京东健康(06618)上半年首发65款新药领跑行业 持续扩大国内医药零售最大平台优势","url":"https://stock-news.laohu8.com/highlight/detail?id=2659375901","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659375901?lang=zh_cn&edition=full","pubTime":"2026-08-13 16:45","pubTimestamp":1786610723,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，2026年上半年，京东健康总收入为人民币409亿元，同比增长15.9%；非国际财务报告准则指标下经营利润35亿元，同比增长40.3%。京东健康坚持以供应链为核心，推动自营、平台及即时零售业务的协同布局，持续扩大专业商品供给，强化自营优势，致力于开放生态，与品牌伙伴和平台商家共同拓展业务增长。从新药上市到精准服务，京东健康正以医药供应链为底座，持续夯实全周期健康服务体系。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479471.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","86618","BK1247","BK1571","BK1583","BK1515","BK1615","SGXZ62798434.SGD","LU0456827905.SGD","09939","LU0051755006.USD","BK1589","SGXZ86797644.SGD","BK1142","BK1591","BK1574","06618","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659137599","title":"京东健康(06618.HK)上半年首发65款新药领跑行业 持续扩大国内医药零售最大平台优势","url":"https://stock-news.laohu8.com/highlight/detail?id=2659137599","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659137599?lang=zh_cn&edition=full","pubTime":"2026-08-13 16:45","pubTimestamp":1786610723,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1589","BK1615","SGXZ86797644.SGD","BK1515","BK1247","BK1161","BK1574","BK1583","LU0051755006.USD","BK1142","SGXZ62798434.SGD","LU0456827905.SGD","09939","06618","BK1571","86618","BK1591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659135560","title":"【券商聚焦】华泰证券首予礼邦医药（09637）买入评级 指肾病管线卡位优","url":"https://stock-news.laohu8.com/highlight/detail?id=2659135560","media":"金吾财讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659135560?lang=zh_cn&edition=full","pubTime":"2026-08-13 13:52","pubTimestamp":1786600358,"startTime":"0","endTime":"0","summary":"金吾财讯 | 华泰证券发布研报指，首次覆盖礼邦医药-B 并给予“买入”评级，目标价51.86港元。据CIC数据，2025年全球高磷血症药物市场规模达18亿美元，2035年有望达64亿美元，且全球仅有这两个创新管线。2023年公司与罗氏达成独家商业化合作，华泰预计美信罗有望于2034年在中国实现约10亿元人民币销售峰值，考虑中国长效制剂渗透率提升、成熟商业化团队支撑以及罗氏供应瓶颈解决。","market":"us","thumbnail":"https://static.szfiu.com/news/20250110/YzMzOTE1NTA2MzA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/YzMzOTE1NTA2MzA=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1988115","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09939","09637","159938","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659603138","title":"超3000只个股飘绿！医药板块集体爆发，多股“20cm”涨停","url":"https://stock-news.laohu8.com/highlight/detail?id=2659603138","media":"滚动播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659603138?lang=zh_cn&edition=full","pubTime":"2026-08-13 12:45","pubTimestamp":1786596300,"startTime":"0","endTime":"0","summary":"沪深两市半日成交额1.59万亿，较上个交易日放量2076亿。截至收盘，沪指涨0.42%，深成指涨0.73%，创业板指涨1.61%。盘面上热点快速轮动，全市场超3000只个股下跌。值得注意的是，今日A股医药板块强势领涨市场，医疗服务、生物制品、化学制药、中药等细分行业板块同步走高，CRO概念股持续拉升，多只个股涨停。自6月29日至今，该股累计涨幅高达276%。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-08-13/doc-inincxkw0106608.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1515","09939","BK1574","BK1161","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659218065","title":"A股午盘 | 沪指涨0.42%创指涨1.61% 医药算力爆发","url":"https://stock-news.laohu8.com/highlight/detail?id=2659218065","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659218065?lang=zh_cn&edition=full","pubTime":"2026-08-13 11:46","pubTimestamp":1786592815,"startTime":"0","endTime":"0","summary":"截至午间收盘，沪指涨0.42%，报3963.15点；深成指涨0.73%，报14519.97点；创业板指涨1.61%，报3660.25点。科创50涨1.90%，报1770.03点。沪深两市半日成交1.59万亿元，较前一交易日放量约2076亿元。点评：消息面上，美股AI算力租赁商Nebius第二季度营收5.823亿美元，同比大增454%，隔夜股价涨超34%；CoreWeave第二财季营收翻倍增长至25.8亿美元，隔夜股价涨超19%。需注意，城地香江8月12日晚间公告称，公司当前主营业务为IDC投资及运营和IDC综合解决方案，暂未有算力租赁相关业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479347.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000905.SH","399300","000688.SH","000001.SH","BK1161","510880","399006","399001","000300.SH","512510","515890","159938","510300","159967","159982","09939","BK1515","BK1574","512880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659182182","title":"今年以来南下资金净买入超3700亿港元，电子医药等行业净买入额居前","url":"https://stock-news.laohu8.com/highlight/detail?id=2659182182","media":"深圳商报·读创","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659182182?lang=zh_cn&edition=full","pubTime":"2026-08-13 10:05","pubTimestamp":1786586745,"startTime":"0","endTime":"0","summary":"今年以来，南下资金持续加仓港股，年内净买入额超3700亿港元。据同花顺数据统计，今年1月1日至8月13日9时，南下资金净买入额达3716.15亿港元。自互联互通机制开通以来，南下资金通过港股通累计净买入额超5.47万亿港元，创历史最高纪录。记者统计发现，今年以来，南下资金单日净买入超百亿港元的交易日超30天，其中8个交易日南下资金单日净买入超200亿港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://stock.eastmoney.com/a/202608133840179957.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.eastmoney.com/a/202608133840179957.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159938","09939","BK1161","BK1574","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659209184","title":"短线情绪持续回暖，把握科技与医药板块结构性机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2659209184","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659209184?lang=zh_cn&edition=full","pubTime":"2026-08-13 09:28","pubTimestamp":1786584494,"startTime":"0","endTime":"0","summary":"　　昨日市场延续反弹，双创指数均涨超1%，全市场超4100股飘红，短线情绪持续回暖。其中连板高标百花医药晋级7连板，成为市场短线情绪标杆，有效带动整个医药板块情绪升温。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/shichangceping/20260813/32333446.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1515","159938","BK1574","BK1161","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659181014","title":"大洋生物：公司目前氟苯下游客户主要为医药及农药生产企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2659181014","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659181014?lang=zh_cn&edition=full","pubTime":"2026-08-13 08:57","pubTimestamp":1786582628,"startTime":"0","endTime":"0","summary":"证券之星消息，大洋生物(003017)08月12日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，根据公开化工资料，氟苯理论上可用作锂电池电解液溶剂、电子新材料中间体。请问公司对外销售的氟苯产品，当前下游客户是否覆盖锂电池电解液、电子新材料相关行业？大洋生物回复：尊敬的投资者，您好。公司目前氟苯下游客户主要为医药及农药生产企业。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081300006971.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","003017","BK0229","09939","BK1574","BK1161","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659186785","title":"前沿生物一高管持股比例降至5%以下；终止在美临床项目 先瑞达医疗2026年上半年预亏 | 医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2659186785","media":"每日经济新闻","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659186785?lang=zh_cn&edition=full","pubTime":"2026-08-13 07:03","pubTimestamp":1786575800,"startTime":"0","endTime":"0","summary":"丨2026年8月13日星期四丨NO.1阳光诺和控股股东、实控人协议转让5%股份过户完成8月12日，阳光诺和发布公告，称公司控股股东、实际控制人利虔与宁波宝隽资产管理有限公司代表的宝隽钱塘6号成长私募证券投资基金的股份协议转让过户登记手续已办理完毕。本次股份过户完成后，利虔持股比例为22.59%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608133839573028.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608133839573028.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","BK1161","06669","09939","159938","BK1100","BK1515","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659865151","title":"新股消息 | 普莱医药港股IPO招股书失效","url":"https://stock-news.laohu8.com/highlight/detail?id=2659865151","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659865151?lang=zh_cn&edition=full","pubTime":"2026-08-13 06:21","pubTimestamp":1786573317,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","09939","BK1574","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659901489","title":"股市必读：华润双鹤新发布《华润双鹤关于控股子公司河南中帅医药科技有限责任公司乙酰唑胺缓释胶囊获得药品注册证书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2659901489","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659901489?lang=zh_cn&edition=full","pubTime":"2026-08-13 01:06","pubTimestamp":1786554373,"startTime":"0","endTime":"0","summary":"公司公告汇总华润双鹤关于控股子公司河南中帅医药科技有限责任公司乙酰唑胺缓释胶囊获得药品注册证书的公告华润双鹤控股子公司中帅医药研发的乙酰唑胺缓释胶囊获得国家药监局颁发的《药品注册证书》，规格为0.5g，注册分类为化学药品3类，视同通过一致性评价。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081300000895.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","BK0175","09939","BK1161","BK0010","BK1515","BK0239","BK0185","600062","159938","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659376904","title":"国泰海通｜医药：国内设备招采月度数据持续回暖，关注医疗器械企业的估值修复","url":"https://stock-news.laohu8.com/highlight/detail?id=2659376904","media":"国泰君安证券研究","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659376904?lang=zh_cn&edition=full","pubTime":"2026-08-12 22:10","pubTimestamp":1786543800,"startTime":"0","endTime":"0","summary":"7月大型医疗设备招采边际持续回暖。设备更新政策持续落地，有望在持续水平拉动医疗设备采购。设备招采复苏不及预期，政策落地不及预期，产品价格波动风险等。报告名称：国内设备招采月度数据持续回暖，关注医疗器械企业的估值修复；报告日期：2026.08.11 报告作者：江珅（分析师），登记编号：S0880525090001赵峻峰（分析师），登记编号：S0880519080017余文心（分析师），登记编号：S0880525040111重要提醒本订阅号所载内容仅面向国泰海通证券研究服务签约客户。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["research"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA5MzEwMDEzNQ==&mid=2650540405&idx=5&sn=86c0c13590de09befa90c08ba2ab1174&chksm=897fc1f128b035fb1fdd627a07400edce4518f37b21c9c3d24fb2155693075f3b6b5e9985010&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["AGNG","BK0201","601211","BK1515","CZA","IEIH","BK0012","BK0276","BK0028","PTH","159883","BK1100","GDOC","159938","02611","LGHT","BK1147","NIFE","REVS","09996","BK1583","BK0188","BK0183","BK0184","BK1564","BK1574","MDEV","LNGR","LCO","09939","MEDX","HART","BK1161","RSPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658205839","title":"8月12日博拓生物涨5.00%，广发医药创新混合发起式A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2658205839","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658205839?lang=zh_cn&edition=full","pubTime":"2026-08-12 16:33","pubTimestamp":1786523603,"startTime":"0","endTime":"0","summary":"证券之星消息，8月12日博拓生物涨5.00%，收盘报40.93元，换手率2.93%，成交量4.37万手，成交额1.77亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为广发基金的广发医药创新混合发起式A。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081200027646.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","688767","BK1515","BK1574","BK0239","BK1161","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658920380","title":"8月12日澳华内镜涨6.68%，圆信永丰医药健康A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2658920380","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658920380?lang=zh_cn&edition=full","pubTime":"2026-08-12 16:32","pubTimestamp":1786523551,"startTime":"0","endTime":"0","summary":"证券之星消息，8月12日澳华内镜涨6.68%，收盘报31.8元，换手率6.42%，成交量8.64万手，成交额2.73亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共16家，其中持有数量最多的公募基金为圆信永丰基金的圆信永丰医药健康A。圆信永丰医药健康A目前规模为2.27亿元，最新净值1.9464，较上一交易日上涨0.26%，近一年下跌2.51%。圆信永丰医药健康A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081200027622.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","BK1515","688212","BK1574","BK1161","150219","09939","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658500924","title":"华人健康：公司以医药产业为核心，构建医药零售、医药营销、终端集采、研发生产四位一体、科学布局的产业生态","url":"https://stock-news.laohu8.com/highlight/detail?id=2658500924","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658500924?lang=zh_cn&edition=full","pubTime":"2026-08-12 15:03","pubTimestamp":1786518195,"startTime":"0","endTime":"0","summary":"公司以医药产业为核心，构建医药零售、医药营销、终端集采、研发生产四位一体、科学布局的产业生态，持续深化工业端产品与终端渠道协同发展。门诊统筹、商保直付是零售药店重要发展方向，公司持续推动符合条件的门店完成资质对接与业务开通，稳步拓展门店覆盖范围。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081200020331.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09939","BK0209","BK1161","BK1515","301408","159938","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658288069","title":"医药调研热度超越半导体！创新药回调，华宝基金港股通创新药ETF失守半年线！CXO韧性十足，药明系逆市飘红","url":"https://stock-news.laohu8.com/highlight/detail?id=2658288069","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658288069?lang=zh_cn&edition=full","pubTime":"2026-08-12 11:02","pubTimestamp":1786503720,"startTime":"0","endTime":"0","summary":"业绩兑现叠加AI制药概念加持，CXO韧性十足，药明生物、药明康德、药明合联逆市飘红，金斯瑞生物科技续涨逾1%。港股通创新药龙头股批量飘绿，百济神州跌2%止步6连阳，翰森制药跌逾3%；再鼎医药延续涨势，股价创年内新高。100%创新药研发标的——港股通创新药ETF华宝冲高回落，现跌1%再失半年线。8月以来，创新药及产业链利好密集，“吃药”行情持续上演。同期医药生物行业的市场关注度大幅攀升。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-12/doc-inimzqcp6895872.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["CHPY","159938","CWC","159316","IBBQ","LNGR","MEDX","TECY","SOXS","09939","SOXQ","SOXL","USD","BK4535","SMHU","BK1574","XSD","VGT","BK1515","MQQQ","TEKX","WX","SMH","SSG","CHPS","CXO","PSI","BK4588","159992","FTXL","FWD","159582","NBDS","SOXY","SMHX","BK4585","EIS","BK1161","FLHK","06978","SOXX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168242546","title":"港股开盘｜港股开盘持平；医药股走强；再鼎医药涨超8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1168242546","media":"港股开盘","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168242546?lang=zh_cn&edition=full","pubTime":"2026-08-12 09:21","pubTimestamp":1786497715,"startTime":"0","endTime":"0","summary":"盘面上，生物医药、资源金属及AI概念活跃，带动个股分化上行；在线娱乐、教育等消费服务类个股则出现回吐，市场风格短线偏向防御与结构性轮动。大型科技股延续弱势，多数回调逾0.5%，仅理想汽车小幅飘红；阿里、腾讯、京东等均低开，或受隔夜美股科技股走软及机构获利了结影响。盘面亮点集中在生物医药与资源股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2488822045.USD","09688","BK4588","KCAI","BK4585","ZLAB","BK4526","VXUS","BK4531","159938","BK1515","BK4548","BK1161","BK1588","BK1574","09939"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kintor.com.cn","stockEarnings":[{"period":"1week","weight":0.1446},{"period":"1month","weight":0.044},{"period":"3month","weight":-0.3116},{"period":"6month","weight":-0.319},{"period":"1year","weight":-0.0952},{"period":"ytd","weight":-0.0306}],"compareEarnings":[{"period":"1week","weight":-0.0184},{"period":"1month","weight":0.0507},{"period":"3month","weight":-0.036},{"period":"6month","weight":-0.0424},{"period":"1year","weight":0.0188},{"period":"ytd","weight":-0.0074}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"开拓药业有限公司是一家主要从事创新药产品研发的投资控股公司。该公司产品致力于解决未满足临床需求的疾病领域，管线主要涵盖皮科（如脱发、痤疮等）及肿瘤适应症。该公司在皮科领域有两款核心药物KX-826及GT20029。该公司在其他疾病领域包括转移性去势抗性前列腺癌（mCRPC）、肝癌、特发性肺纤维化、恶性血液疾病及多种实体瘤等。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.020286},{"month":2,"riseRate":0.666667,"avgChangeRate":0.174983},{"month":3,"riseRate":0.333333,"avgChangeRate":0.058562},{"month":4,"riseRate":0.666667,"avgChangeRate":0.374359},{"month":5,"riseRate":0.5,"avgChangeRate":0.006013},{"month":6,"riseRate":0.285714,"avgChangeRate":-0.081543},{"month":7,"riseRate":0.571429,"avgChangeRate":0.098094},{"month":8,"riseRate":0.285714,"avgChangeRate":-0.044476},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.129033},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.103242},{"month":11,"riseRate":0.666667,"avgChangeRate":0.073526},{"month":12,"riseRate":0.166667,"avgChangeRate":-0.185801}],"exchange":"SEHK","name":"开拓药业-B","nameEN":"KINTOR PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供开拓药业-B(09939)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"开拓药业-B,09939,开拓药业-B股票,开拓药业-B股票老虎,开拓药业-B股票老虎国际,开拓药业-B行情,开拓药业-B股票行情,开拓药业-B股价,开拓药业-B股市,开拓药业-B股票价格,开拓药业-B股票交易,开拓药业-B股票购买,开拓药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供开拓药业-B(09939)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}